Effect of TAK-147, a novel AChE inhibitor, on cerebral energy metabolism

Neurobiology of Aging

Volumn 17, Issue 6, 1996, Pages 849-857

  Nakayama, Takahiro ^a   Takahashi, Hideki ^a   Miyamoto, Masaomi ^a   Goto, Giichi ^a   Nagai, Yasuo ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

31P magnetic resonance spectroscopy; acetylcholinesterase inhibitor; aged Fischer 344 rat; ATP; local cerebral glucose utilization (LCGU); phosphocreatine (PCr)

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHOLINESTERASE INHIBITOR; CREATINE PHOSPHATE; ZANEPEZIL;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; AUTORADIOGRAPHY; BENZAZEPINES; BRAIN CHEMISTRY; CHOLINESTERASE INHIBITORS; ENERGY METABOLISM; GLUCOSE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHOCREATINE; RATS; RATS, INBRED F344;

EID: 0030294475     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(96)00077-2     Document Type: Article

References (58)

1. 1. Bassant, M. H.; Jazat, F.; Lamour, Y. Tetrahydroaminoacridine and physostigmine increase cerebral glucose utilization in specific cortical and subcortical regions in the rat. H. Cereb. Blood Flow Metab. 13: 855-864; 1993.
2. 2. Beck, T.; Krieglstein, J. The effects of tifluadom and ketazocine on behavior, dopamine turnover in the basal ganglia and local cerebral glucose utilization of rats. Brain Res. 381:327-335; 1986.
3. 3. Beck, T.; Vogg, P.; Krieglstein, J. Effects of the indirect dopamino-mimetic diethylpemoline on local cerebral glucose utilization and local cerebral blood flow in the conscious rat. Eur. J. Pharmacol. 125:437-447; 1986.
4. 4. Becker, R.; Giacobini, E. Advances in the therapy of Alzheimer's disease: Issues in the study and development of cholinomimetic therapies. In: Giacobini, E.; Becker, R., eds. Current research in Alzheimer therapy. New York: Taylor and Francis; 1988:113-122.
5. 18F scan in Alzheimer's disease and multi-infarct dementia. Arch. Neurol. 40:711-714; 1983.
6. 6. Borgstrom, L.; Norberg, K.; Siesjo, B. K. Glucose consumption in rat cerebral cortex in normoxia, hypoxia and hypercapnia. Acta Physiol. Scand. 96:569-574; 1976.
7. 7. Bowen, D. M.; Davison, A. N.; Francis, P. T.; Palmer, A. M.; Pearce, B. R. Neurotransmitter and metabolic dysfunction in Alzheimer's dementia: Relationship to histopathological features. In: Hahn, H. P., ed. Interdisciplinary topics in gerontolgy, vol. 19. Basel: Karger; 1985: 156-174.
8. 8. Bryan, R. M., Jr.; Hawkins, R. A.; Mans, A. M.; Davis, D. W.; Page, R. B. Cerebral glucose utilization in awake unstressed rats. Am. J. Physiol. 244:C270-275; 1983.
9. 9. Crawford, J. R.; Besson, J. A. O.; Evans, N. T. S.; Roeda, D.; Kulkarni, V.; Parker, D.M.; Ebmeir, K.P.; Allan, K.M.; Mallard, J. R. Cerebral blood flow in Alzheimer's disease imaged by positron emission tomography: The effects of physostigmine infusion. In: Kalousek, M., ed. Janssen symposium 17 Geronto Psychiatrie. Neuss: Janssen; 1991.
10. 10. Crawford, J. R.; Besson, J. A. O.; Ebmeier, K. P. Dementia: The role of neurotransmitter deficits. In: Dinan, T. G., ed. Principles and practice of biological psychiatry. Clinical Neuroscience; London: 1991:105-134.
11. 11. Cutler, N. R.; Murphy, M. F.; Nash, R. J.; Prior, P. L.; De Luna, D. M. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-o1-maleate(HP-029) in Alzheimer's disease: Preliminary findings. J. Clin. Pharmacol. 30: 556-561; 1990.
12. 12. Dam, M.; Rapoport, S. I.; London, E. D. Aging and cholinergic system: A 2-deoxy-glucose study in the rat brain. Monogr. Neural Sci. 11:62-67; 1984.
13. 13. Davis, K. L.; Thai, L. J.; Gamzu, E. R.; Davis, C. S.; Woolson, R. F.; Gracon, S. I.; Drachman, D. A.; Schneider, L. S.; Whitehouse, P. J.; Hoover, T. M.; Morris, J. C.; Kawas, C. H.; Knopman, D.S.; Eari, N. L.; Kumar, V.; Doody, R. S. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N. Engl. J. Med. 327:1253-1259; 1992.
14. 14. DeJong, R. N.; Itabashi, H. H.; Olson, J. R. Memory loss due to hippocampal lesions. Arch. Neurol. 20:339-348; 1969.
15. 15. Duara, R.; Grady, C.; Haxby, J.; Sundaram, M.; Cutler, N. R.; Heston, L.; Moore, A.; Schlageter, N.; Larson, S.; Rapoport, S. I. Positron emission tomography in Alzheimer's disease. Neurology 36:879-887; 1986.
16. 16. Eagger, S. A.; Levy, R.; Sahakian, B. J. Tacrine in Alzheimer's disease. Lancet i:989-992; 1991.
17. 17. Ebmeier, K. P.; Hunter, R.; Curran, S. M.; Dougal, N. J.; Murray, C. L.; Wyper, D. J.; Patterson, J.; Hanson, M. T.; Siegfried, K.; Goodwin, G. M. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology (Berlin) 108:103-109; 1992.
18. 18. Edeline, J. M.; Hars, B.; Maho, C.; Hennevin, E. Transient and prolonged facilitation of tone-evoked responses induced by basal forebrain stimulations in the rat auditory cortex. Exp. Brain Res. 978:373-386; 1994.
19. 19. Edvinsson, L.; Falck, B.; Owman, C. Possibilities for a cholinergic action on smooth musculature and on sympathetic axons in brain vessels mediated by muscarinic and nicotinic receptors. J. Pharmacol. Exp. Ther. 200:117-126; 1977.
20. 20. Fielding, S.; Cornfeldt, M. L.; Szewczak, M. R.; Ellis, D. B.; Huger, F. P.; Davis, K.; Wilker, J. C.; Shutske, G. M. HP-029, a new drug for the treatment of Alzheimer's disease: Its pharmacological profile. In: Kewits, H.; Thompson, T.; Bickel, U., eds. Pharmacological interventions on central cholinergic mechanisms in sinile dementia (Alzheimer's disease). W. Zuckschwerdt; München: 1989.
21. 21. Foster, N. L.; Chase, T. N.; Mansi, L.; Brooks, R.; Fedio, P.; Patronas, N. J.; Di Chiro, G. Cortical abnormalities in Alzheimer's disease. Ann. Neurol. 6:649-654; 1984.
22. 22. Friedland, R. P.; Budinger, T. F.; Koss, E.; Ober, B. A. Alzheimer's disease: Anterior-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci. Lett. 53:235-240; 1985.
23. 23. Geaney, D. P.; Soper, N.; Shepstone, B. J.; Cowen, P. J. Effects of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. Lancet i: 1484-1487; 1990.
24. 24. Giacobini, E. Models and strategies of cholinergic therapy of Alzheimer disease. In: Dowdall, M. J., ed. Cellular and molecular basis of cholinergic function. England: Ellis Horwood; 1987:882-901.
25. 25. Gjedde, A. Does deoxyglucose uptake in the brain reflect energy metabolism? Biochem. Pharmacol. 36:1853-1861; 1987.
26. 26. Gustavson, L.; Edwinson, L.; Dahlgren, N.; Hagberg, B.; Risberg, J.; Rosen, I.; Ferno, H. Intravenous physostigmine treatment of Alzheimer's disease evaluate by psychometric testing, regional cerebral blood flow measurement and EEG. Psychopharmacology (Berlin) 93: 31-35; 1987.
27. 27. Hardy, J.; Adolfsson, R.; Alafuzoff, I.; Bucht, G.; Marcusson, J.; Nyberg, P.; Perdahl, E.; Wester, P.; Winblad, B. Transmitter deficits in Alzheimer's disease. Neurochem. Int. 7:545-563; 1985.
28. 28. Hars, B.; Maho, C.; Edeline, J. M.; Hennevin, E. Basal forebrain stimulation facilitates tone-evoked responses in the auditory cortex of awake rat. Neuroscience 56:61-74; 1993.
29. 29. Heistad, D. D.; Marcus, M. L.; Said, S. I.; Gross, P. M. Effect of acetylcholine and vasoactive intestinal peptide on cerebral blood flow. Am. J. Physiol. 239:H73-H80; 1980.
30. 30. Hirai, K.; Kato, K.; Nakayama, T.; Murakoshi, H.; Ishihara, Y.; Goto, G.; Miyamoto, M. Characteristics of neuropharmacological effects of TAK-147, a novel acetylcholinesterase inhibitor, in vitro. Soc. Neurosci. Abstr. 19:1812; 1993.
31. 99mTc-HMPAO SPET imaging. Br. J. Psychiary 158:351-357; 1991.
32. 32. Ishihara, Y.; Hirai, K.; Miyamoto, M.; Goto, G. Central cholinergic agents. IV. Synthesis and evaluation of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanones and their analogs as central selective acetylcholinesterase inhibitors. J. Med. Chem. 37:2292-2299; 1994.
33. 33. Kauppinen, R. A.; Williams, S. R. Nuclear magnetic resonance spectroscopy studies of the brain. Prog. Neurobiol. 44:87-118; 1994.
34. 18F]-fluorodeoxyglucose method. J. Cereb. Blood Flow Metab. 2:163-171; 1982.
35. 35. Kuschinsky, W.; Suda, S.; Bunger, R.; Yaffe, S.; Sokoloff, L. The effect of intravenous norepinephrine on the coupling between glucose utilization and cerebral blood flow in the rat brain. Pflugers Arch. 398:134-138; 1983.
36. 36. Kuschinsky, W.; Suda, S.; Sokoloff, L. Influence of γ-hydroxybutyrate on the relationship between local cerebral glucose utilization and local cerebral blood flow in the rat brain. J. Cereb. Blood Flow Metab. 5:58-64; 1985.
37. 37. Kuschinsky, W.; Wahl, M.; Neiss, A. Evidence for cholinergic dilatory receptors in pial arteries of cats: A microapplication study. Pfluegers Arch. 347:199-208; 1974.
38. 38. Marshall, J. F.; Berrios, N. Movement disorders of aged rats: Reversal by dopamine receptor stimulation. Science 206:477-479; 1979.
39. 39. McCulloch, J.; Savaki, H. E.; Jehle, J.; Sokoloff, L. Local cerebral glucose utilization in hypothermic and hyperthermic rats. J. Neurochem. 39:255-258; 1982.
40. 40. Miller, E. Impaired recall and the memory, disturbance in presenile dementia. Br. J. Soc. Clin. Psychol. 14:73-79; 1975.
41. 41. Miyamoto, M.; Takahashi, H.; Nishiyama, M.; Ishihara, Y.; Goto, G. Effects of TAK-147, a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models. Soc. Neurosci. Abstr. 19:1812; 1993.
42. 42. Mohs, R. C.; Davis, B. M.; Johns, C. A.; Mathe, A. A.; Greenwald, B. S.; Horvath, T. B.; Davis, K. L. Oral physostigmine treatment of patients with Alzheimer's disease. Am. J. Psychiatry. 142:28-33; 1985.
43. 43. Nissen, M. J.; Knopman, D. S.; Schacter, D. L. Neurochemical dissociation of memory systems. Neurology 37:789-794; 1987.
44. 44. Perry, E. K.; Tomlinson, B. E.; Blessed, G.; Bergmann, K.; Gibson, P. H.; Perry, R. H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2:1457-1459; 1978.
45. 45. Siegfried, K.; Exner, M. Subacute effects of velnacrine (HP-029) in a placebo controlled cross-over study in patients with Alzheimer's disease. Abstracts of the 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum (CINP), vol 2. 235:10-14; 1990.
46. 46. Smith, C. B.; Goochee, C.; Rapoport, S. I.; Sokoloff, L. Effects of aging on local rates of cerebral glucose utilization in the rat. Brain. 103:351-365; 1980.
47. 47. Smith, C. B. Aging and changes in cerebral energy metabolism. Trends Neurosci. 7:203-208; 1984.
48. 14C]-deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28:897-916; 1977.
49. 49. Sokoloff, L. Relation between physiological function and energy metabolism in the central nervous system. J. Neurochem. 29:13-26; 1977.
50. 50. Summers, W. K.; Majowski, L. V.; Marsh, G. M.; Tachiki, K.; Kling, A. Oral tetra-hydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 315:1241-1245; 1986.
51. 51. Sunderland, T.; Tariot, P. N.; Weingartner, H.; Murphy, D. L.; Newhouse, P. A.; Meuller, E. A.; Cohen, R. M. Pharmacological modelling of Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry. 10:599-610; 1986.
52. 52. Takahashi, H.; Nishiyama, M.; Ishihara, Y.; Goto, G.; Miyamoto, M. Effects of TAK-147, a novel acetylcholinesterase inhibitor, on learning impairments in aged animals. Jpn. J. Pharmacol. 64(Suppl.I):356P; 1994.
53. 53. Victor, M.; Angeline, J. B.; Mancall, E. L.; Fisher, C. M. Memory loss with lesions of hippocampal formation. Arch. Neurol. 5:244-263; 1961.
54. 54. Weinberger, J.; Greenberg, J. H.; Waldman, M. T. G.; Sylvestro, A.; Reivich, M. The effect of scopolamine on local glucose metabolism in the rat brain. Brain Res. 177:337-345; 1979.
55. 55. Werner, W.; Rey, H. G.; Wielinger, H. Uber die eigenschaften eines neuen chromagens fur die blutzuckerbestimmung nach der GOD/POD-methode. Z. Anal. Chem. 252:224-228; 1970.
56. 56. Wree, A.; Schleicher, A. The determination of the local cerebral glucose utilization with the 2-deoxyglucose method. Histochemistry 90: 109-121; 1988.
57. 57. Wyper, D. J.; Teasdale, E.; Patterson, J.; Montaldi, D.; Hunter, R. Abnormalities in rCBF and computed tomography in patients with Alzheimer's disease and in controls. Br. J. Radiol. 66(781):23-27; 1993.
58. 58. Zec, R. Effects of physostigmine on recognition memory in AD patients: A comparative review. In: Giacobini, E; Becker, R., eds. Current research in Alzheimer therapy. New York: Taylor and Francis; 1988:153-162.